Targeting Immune Cell Trafficking - Insights From Research Models and Implications for Future IBD Therapy.

In a phase II trial for the treatment of moderate-to-severe CD (OPERA) clinical endpoints did not reach statistical significance in comparison to placebo ( 39 , 40 ), but treatment led to a reduction of soluble MAdCAM-1 and to an increase of circulating β7 + central memory T cells and elevated CCR9 gene expression ( 41 ).

also in 111,027 other papers